Real-world experience with the new Watchman FLX device: Data from two high-volume Sicilian centers. The FLX-iEST registry.
closure left atrial appendage
interventional devices/innovation
new devices
stroke
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
11
04
2022
received:
21
11
2021
accepted:
08
05
2022
pubmed:
21
5
2022
medline:
14
7
2022
entrez:
20
5
2022
Statut:
ppublish
Résumé
The Watchman-FLX left atrial appendage closure (LAAC) device presents innovative features: higher conformability, reduced length, closed distal "flex-ball" during deployment, and flattened surface. We report our real-world experience with the Watchman-FLX device in two centers with consolidated LAAC expertise. We enrolled 200 consecutive Watchman-FLX patients (2019-2021) in a nonrandomized double-center registry; procedural data and follow-up for midterm clinical outcomes were collected. A control group of 100 patients treated with first-generation Watchman (2.5) was included. According to mean CHAD Our registry showed a high procedural success rate of the Watchman-FLX in a high-risk population. According to our experience, the main advantages include easy implanting and repositioning, absence of embolization, good LAA sealing, and low rate of complications in the follow-up period.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-160Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.
Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion-an update. EuroIntervention. 2020;15:1133-1180.
Freeman JV, Varosy P, Price MJ, et al. The NCDR left atrial appendage occlusion registry. J Am Coll Cardiol. 2020;75:1503-1518.
Mazzone P, D'Angelo G, Regazzoli D, et al. Percutaneous left atrial appendage closure with WATCHMAN™ device: peri-procedural and mid-term outcomes from the TRAPS registry. J Interv Card Electrophysiol. 2018;52:47-52.
Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016;37:2465-2474.
Boersma LV, Ince H, Kische S, et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: final 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage. Circ Arrhythm Electrophysiol. 2019;12:e006841.
Holmes DR, Jr., Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1-12.
Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964-2975.
Fauchier L, Cinaud A, Brigadeau F, et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol. 2018;71:1528-1536.
Alkhouli M, Busu T, Shah K, Osman M, Alqahtani F, Raybuck B. Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion: a meta-analysis. JACC Clin Electrophysiol. 2018;4:1629-1637.
Tzikas A, Holmes DR Jr., Gafoor S, et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. EuroIntervention. 2016;12:103-111.
Tzikas A, Holmes DR, Jr., Gafoor S, et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace. 2017;19:4-15.
Frazzetto M, Costa G, Scandura S, Tamburino C, Grasso C. Bailout additional Watchman FLX device implantation for left atrial appendage closure. Cardiovasc Revasc Med. Published online January 31, 2022. S1553-8389. https://doi.org/10.1016/j.carrev.2022.01.022.
Grygier M, Markiewicz A, Araszkiewicz A, et al. Watchman FLX: the initial Polish experience with a new device for left atrial appendage occlusion. Kardiol Pol. 2020;78:240-242.
Cruz-Gonzalez I, Korsholm K, Trejo-Velasco B, et al. Procedural and short-term results with the new watchman FLX left atrial appendage occlusion device. JACC Cardiovasc Interv. 2020;13:2732-2741.
Korsholm K, Samaras A, Andersen A, Jensen JM, Nielsen-Kudsk JE. The watchman FLX device: first European experience and feasibility of intracardiac echocardiography to guide implantation. JACC Clin Electrophysiol. 2020;6:1633-1642.
Galea R, Mahmoudi K, Grani C, et al. Watchman FLX vs. Watchman 2.5 in a dual-center left atrial appendage closure cohort: the WATCH-DUAL study. Europace. Published online March 7, 2022. https://doi.org/10.1093/europace/euac021
Kar S, Doshi SK, Sadhu A, et al. Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. Circulation. 2021;143:1754-1762.